BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 38091052)

  • 21. Modified cyclophosphamide, vincristine, doxorubicin, and methotrexate (CODOX-M)/ifosfamide, etoposide, and cytarabine (IVAC) therapy with or without rituximab in Japanese adult patients with Burkitt lymphoma (BL) and B cell lymphoma, unclassifiable, with features intermediate between diffuse large B cell lymphoma and BL.
    Maruyama D; Watanabe T; Maeshima AM; Nomoto J; Taniguchi H; Azuma T; Mori M; Munakata W; Kim SW; Kobayashi Y; Matsuno Y; Tobinai K
    Int J Hematol; 2010 Dec; 92(5):732-43. PubMed ID: 21120644
    [TBL] [Abstract][Full Text] [Related]  

  • 22. 'MACHO' chemotherapy for stage IV B cell lymphoma and B cell acute lymphoblastic leukaemia of childhood. United Kingdom Children's Cancer Study Group (UKCCSG).
    Hann IM; Eden OB; Barnes J; Pinkerton CR
    Br J Haematol; 1990 Nov; 76(3):359-64. PubMed ID: 2261346
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Characteristics of Central Nervous System (CNS) Involvement in Children With Non-Hodgkin's Lymphoma (NHL) and the Diagnostic Value of CSF Flow Cytometry in CNS Positive Disease.
    Huang S; Jin L; Yang J; Duan Y; Zhang M; Zhou C; Zhang YH
    Technol Cancer Res Treat; 2021; 20():15330338211016372. PubMed ID: 34060372
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of the addition of rituximab to CODOX-M/IVAC for Burkitt's lymphoma: a retrospective analysis.
    Barnes JA; Lacasce AS; Feng Y; Toomey CE; Neuberg D; Michaelson JS; Hochberg EP; Abramson JS
    Ann Oncol; 2011 Aug; 22(8):1859-64. PubMed ID: 21339382
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Therapy for Burkitt's lymphoma according to the BL-M-04 protocol: 12-year experience].
    Baryakh EA; Tyurina NG; Vorobyev VI; Gemdzhyan EG; Mangasarova YK; Klyasova GA; Kovrigina AM; Obukhova TN; Zvonkov EE; Vernyuk MA; Chervontseva AM; Polyakov YY; Misyurina АЕ; Valiev TT; Zherebtsova VA; Magomedova AU; Galstyan GM; Yatskov KV; Nesterova ES; Vorobyev AI; Kravchenko SK
    Ter Arkh; 2015; 87(7):4-14. PubMed ID: 26390720
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Long term efficacy of COPADM regimen in the treatment of 20 patients with Burkitt lymphoma].
    Yang D; Wang P; Chen J; Li CX; Zhang Y; Chen XC; Wu DP
    Zhonghua Xue Ye Xue Za Zhi; 2018 Aug; 39(8):645-649. PubMed ID: 30180465
    [No Abstract]   [Full Text] [Related]  

  • 27. Clinical Characteristics and Outcomes of AIDS-Related Burkitt Lymphoma in China: A Retrospective Single-Center Study.
    Liu R; Zhao H; Xiao G; Tao Y; Tang X; Feng L; Liao B; Liu B; Guan J; Li L; Chen Z; He H; You H
    Technol Cancer Res Treat; 2024; 23():15330338231214236. PubMed ID: 38179657
    [No Abstract]   [Full Text] [Related]  

  • 28. Clinical characteristics and outcomes of newly diagnosed patients with HIV-associated aggressive B-cell NHL in China.
    Wang C; Liu J; Lei H; Li Y; Wu J; Guo B; Hu R; Liu T; Wu J; Ding Y; Hu C; Liang S; Xiao C; Liang X; Huang D; Yang T; Zhang W; Yang Z; Li J; Nan Y; Li Q; Xiang Y; Li Z; Wu Y; Liu Y
    J Cell Mol Med; 2022 Oct; 26(19):5067-5077. PubMed ID: 36056692
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Comparison of the efficacy of CCCG-97 and BFM-90 protocols in the treatment for children with mature B-cell non-Hodgkin's lymphoma].
    Meng JH; Gao YJ; Lu FJ; Zhai XW; Wang HS; Li J
    Zhonghua Zhong Liu Za Zhi; 2012 Mar; 34(3):222-7. PubMed ID: 22780979
    [TBL] [Abstract][Full Text] [Related]  

  • 30. B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma.
    Snuderl M; Kolman OK; Chen YB; Hsu JJ; Ackerman AM; Dal Cin P; Ferry JA; Harris NL; Hasserjian RP; Zukerberg LR; Abramson JS; Hochberg EP; Lee H; Lee AI; Toomey CE; Sohani AR
    Am J Surg Pathol; 2010 Mar; 34(3):327-40. PubMed ID: 20118770
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Long-term clinical outcome of children and adolescents with Burkitt's lymphoma treated with rituximab combined with modified NHL-BFM-90 regimen].
    Li YX; Yin QS; Ai H; Mi RH; Zhang LN; Li YF; Wei XD; Song YP
    Zhonghua Yi Xue Za Zhi; 2019 Feb; 99(8):605-610. PubMed ID: 30818930
    [No Abstract]   [Full Text] [Related]  

  • 32. [A collaborative study on children with mature B-cell non-Hodgkin's lymphoma in China].
    ; ; ;
    Zhonghua Er Ke Za Zhi; 2014 Sep; 52(9):649-54. PubMed ID: 25476425
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Burkitt lymphoma-a retrospective analysis of data from the Registry of the Czech Lymphoma Study Group with external validation of the Burkitt lymphoma International Prognostic Index.
    Sýkorová A; Procházka V; Móciková H; Janíková A; Pytlík R; Belada D; Benešová K; Klener P; Ďuraš J; Smolej L; Campr V; Blahovcová P; Trněný M
    Neoplasma; 2022 Dec; 69(6):1466-1473. PubMed ID: 36591807
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patients.
    Patte C; Auperin A; Gerrard M; Michon J; Pinkerton R; Sposto R; Weston C; Raphael M; Perkins SL; McCarthy K; Cairo MS;
    Blood; 2007 Apr; 109(7):2773-80. PubMed ID: 17132719
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Clinical features and prognosis of children with mature B-cell non-Hodgkin's lymphoma: an analysis of 28 cases].
    Chen ZS; Zheng YZ; Chen YQ; Gao QL; Li J; Shen JZ
    Zhongguo Dang Dai Er Ke Za Zhi; 2018 Jun; 20(6):470-474. PubMed ID: 29972121
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Specific cytogenetic abnormalities are associated with a significantly inferior outcome in children and adolescents with mature B-cell non-Hodgkin's lymphoma: results of the FAB/LMB 96 international study.
    Poirel HA; Cairo MS; Heerema NA; Swansbury J; Aupérin A; Launay E; Sanger WG; Talley P; Perkins SL; Raphaël M; McCarthy K; Sposto R; Gerrard M; Bernheim A; Patte C;
    Leukemia; 2009 Feb; 23(2):323-31. PubMed ID: 19020548
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Clinical analysis of a modified LMB89 Group C regimen in the treatment of pediatric high-risk Burkitt lymphoma].
    Zhang M; Jin L; Yang J; Duan YL; Huang S; Zhou CJ; Zhang YH
    Zhonghua Xue Ye Xue Za Zhi; 2019 Aug; 40(8):633-638. PubMed ID: 31495128
    [No Abstract]   [Full Text] [Related]  

  • 38. [The clinical characteristics and outcomes of 16 Burkitt' s lymphoma with testicular involvement].
    Huang S; Jin L; Yang J; Duan YL; Zhang M; Zhou CJ; Zhang YH
    Zhonghua Xue Ye Xue Za Zhi; 2016 Sep; 37(9):768-773. PubMed ID: 27719719
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Results of treatment of advanced-stage Burkitt's lymphoma and B cell (SIg+) acute lymphoblastic leukemia with high-dose fractionated cyclophosphamide and coordinated high-dose methotrexate and cytarabine.
    Murphy SB; Bowman WP; Abromowitch M; Mirro J; Ochs J; Rivera G; Pui CH; Fairclough D; Berard CW
    J Clin Oncol; 1986 Dec; 4(12):1732-9. PubMed ID: 3491184
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical characteristics and outcome analysis of pediatric B-cell non-Hodgkin's lymphoma. Experience with FAB-LMB 96 and UKCCSG B-cell NHL guidelines in a developing country.
    Ahmad N; Zaidi A; Badar F; Maaz AU; Akram MS
    Asia Pac J Clin Oncol; 2010 Mar; 6(1):49-56. PubMed ID: 20398038
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.